This title appears in the Scientific Report :
2018
Please use the identifier:
http://dx.doi.org/10.1002/jlcr.3578 in citations.
Development of novel radionuclides for medical applications
Development of novel radionuclides for medical applications
Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to non-standard positron emitters (e.g. 64Cu, 86Y, 124I, 73Se) and novel therapeutic radionuclides emitting low-range β-...
Saved in:
Personal Name(s): | Spahn, Ingo |
---|---|
Qaim, Syed M. (Corresponding author) | |
Contributing Institute: |
Nuklearchemie; INM-5 |
Published in: | Journal of labelled compounds and radiopharmaceuticals, 61 (2018) S. 126-140 |
Imprint: |
New York, NY [u.a.]
Wiley
2018
|
DOI: |
10.1002/jlcr.3578 |
PubMed ID: |
29110328 |
Document Type: |
Journal Article |
Research Program: |
Neuroimaging |
Publikationsportal JuSER |
Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to non-standard positron emitters (e.g. 64Cu, 86Y, 124I, 73Se) and novel therapeutic radionuclides emitting low-range β- particles (e. g. 67Cu, 186Re), conversion or Auger electrons (e.g. 117mSn, 77Br) and α-particles (e.g. 225Ac). A brief account of various aspects of development work (i.e. nuclear data, targetry, chemical processing, quality control) is given. For each radionuclide under consideration the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out. |